Figure 1.
Flowchart of patient numbers through the study.
Table 1.
Medications taken by study patients.
Table 2.
Mean changes in outcome measures.
Figure 2.
Changes in plasma levels of MHPG in the manic state for BDI patients.
Each point represents the mean value. The significance of differences was calculated using repeated-measures ANOVA with post hoc Bonferroni testing (*p<0.05). Patients had significantly reduced plasma levels of MHPG throughout the manic syndrome, response and remission stages (repeated-measures ANOVA; F2,46 = 7.370, p = 0.002).